The stock of Emergent Biosolutions Inc (NYSE: EBS) has decreased by -3.44 when compared to last closing price of 6.83. Despite this, the company has experienced a 6.03% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-25 that LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) — ABeam Consulting (USA) Ltd. (“ABeam US”) and Millennium EBS, a BlueOne Card Inc. subsidiary, have announced a strategic collaboration under a newly signed Master Services Agreement (MSA) to jointly promote the Millennium EBS Payment Hub: ISO 20022 Transformer.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
EBS has 36-month beta value of 2.12. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EBS is 51.92M, and currently, short sellers hold a 15.39% ratio of that float. The average trading volume of EBS on June 27, 2025 was 1.22M shares.
EBS’s Market Performance
The stock of Emergent Biosolutions Inc (EBS) has seen a 6.03% increase in the past week, with a 1.46% rise in the past month, and a 34.04% gain in the past quarter. The volatility ratio for the week is 5.36%, and the volatility levels for the past 30 days are at 5.32% for EBS. The simple moving average for the past 20 days is 2.07% for EBS’s stock, with a -14.31% simple moving average for the past 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at 10.61% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.32% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Katkin Keith, who sale 7,844 shares at the price of $6.30 back on May 23 ’25. After this action, Katkin Keith now owns 86,431 shares of Emergent Biosolutions Inc, valued at $49,417 using the latest closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.32 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.14. The total capital return value is set at -0.04. Equity return is now at value -21.63, with -8.15 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is -0.88.
Currently, EBITDA for the company is 36.9 million with net debt to EBITDA at 4.86. When we switch over and look at the enterprise to sales, we see a ratio of 0.91. The receivables turnover for the company is 4.71for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.32.
Conclusion
To put it simply, Emergent Biosolutions Inc (EBS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
